-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 39476 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCDNA6-V5/His.b
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5212
-
Vector typeMammalian Expression
-
Selectable markersBlasticidin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameARID1A
-
SpeciesH. sapiens (human)
-
Mutationexpresses ARID1A aa1759-2285
-
GenBank IDNM_006015.4
-
Entrez GeneARID1A (a.k.a. B120, BAF250, BAF250a, BM029, C1orf4, CSS2, ELD, MRD14, OSA1, P270, SMARCF1, hELD, hOSA1)
-
Tags
/ Fusion Proteins
- V5 (C terminal on backbone)
- His (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site XhoI (not destroyed)
- 5′ sequencing primer CMV-fwd, T7-promoter
- 3′ sequencing primer BGH-rev, V5-rev (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Encodes the C-terminus of ARID1A.
Note that although the nucleotide sequence cloned in this plasmid starts with aa 1746, the cloning strategy was designed so that aa 1746- 1758 will not be translated, as there is no ATG start site. The actual ATG start site is at aa 1759.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA6-ARID1A 1759-2285 was a gift from Ie-Ming Shih (Addgene plasmid # 39476 ; http://n2t.net/addgene:39476 ; RRID:Addgene_39476) -
For your References section:
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Guan B, Wang TL, Shih IeM. Cancer Res. 2011 Nov 1;71(21):6718-27. Epub 2011 Sep 7. 10.1158/0008-5472.CAN-11-1562 PubMed 21900401